首页分子通1-{5-tert-butyl-2-[3-(3-dimethylamino-azetidin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea formate salt
1-{5-tert-butyl-2-[3-(3-dimethylamino-azetidin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea formate salt
1-{5-tert-butyl-2-[3-(3-dimethylamino-azetidin-1-ylmethyl)phenyl]-2H-pyrazol-3-yl}-3-{(1S,4R)-4-[3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea formate salt
Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.